A Study of Cizutamig in Systemic Sclerosis
NCT07158996 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2025-09-08
Summary
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with SSc.
Conditions
- Systemic Sclerosis (SSc)
Interventions
- DRUG
-
Biological: cizutamig
Cizutamig will be dosed according to the protocol.
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-04
- Primary Completion
- 2026-12-01
- Completion
- 2027-08-31
More Related Trials
-
Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
NCT04925557 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis
NCT05462522 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
NCT01541618 ·Status: COMPLETED
-
Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
NCT06210945 ·Status: SUSPENDED ·Phase: PHASE2
-
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design
NCT01945359 ·Status: COMPLETED
-
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
NCT01181089 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
NCT01191996 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504 ·Status: RECRUITING ·Phase: PHASE3
-
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
NCT00228397 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
NCT03315923 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Pilot-Study of Sirolimus for the Treatment of Systemic Sclerosis
NCT03365869 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients
NCT05596526 ·Status: RECRUITING ·Phase: PHASE4
-
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
NCT06058091 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM)
NCT05828901 ·Status: TERMINATED
-
Multiple Sclerosis: Chi3L1 and Treatment Efficacy
NCT04289675 ·Status: COMPLETED
-
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
NCT01395316 ·Status: COMPLETED ·Phase: PHASE4
-
COMparison Between All immunoTherapies for Multiple Sclerosis.
NCT03193866 ·Status: COMPLETED
-
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT01416155 ·Status: COMPLETED ·Phase: PHASE2
-
Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
NCT01188811 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.
NCT05777902 ·Status: TERMINATED ·Phase: PHASE4
-
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
NCT01071512 ·Status: COMPLETED ·Phase: NA
-
Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoid Dendritic Cells in Multiple Sclerosis
NCT05451069 ·Status: UNKNOWN
-
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
NCT01623596 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
NCT02253264 ·Status: COMPLETED ·Phase: PHASE1
-
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
NCT00616733 ·Status: COMPLETED ·Phase: PHASE1